Material impact of the immunohistochemical technique in patients with breast cancer in Matanzas
Abstract
Introduction: breast cancer is a health problem due to its high incidence and mortality. Immunohistochemistry is a technique that allows precise treatment, but it is expensive and the province of Matanzas does not have the necessary equipment for its performance. It is known that patients with Luminal A type breast cancer do not benefit from the use of chemotherapy, due to this some patients are over-treated, determining an important material impact.
Objective: to identify the material impact on the National Health System due to the delay in obtaining the results of the immunohistochemical technique at the Provincial Oncology Service of Matanzas.
Methods: a descriptive, longitudinal and retrospective study was carried out.
Results: of the population studied, one fifth was Luminal A, and of these, two thirds did not receive hormonal treatment, with predominance between the sixth and seventh decades of life. The time between taking the sample and obtaining the immunohistochemical result was unknown in most cases and the material impact was high.
Conclusions: the delay in obtaining the results of the immunohistochemical technique represents an excessive waste of resources on the Provincial Cancer Center of Matanzas.
Downloads
References
1- Ríos Hidalgo, N. Patología General. ECIMED 2014: 19. ISBN 978-959-212-884-2.
2- Surenkok S, Tahberer E, Cinkaya A, Kodaz H, Deger A. Metaplastic breast cancer: A case report. J Pak MedAssoc. 2018 Mar;68(3):466-468. PMID: 29540888.
3- Lluch A, Eroles P, Bosch A, Pérez-Fidalgo JA. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. PMID: 22178455.
4- Soriano García JL y Col. Manual de Cáncer de mama. La Habana. 2017
5- Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28. PMID: 29593010.
6- Poveda Miranda, J. S. Perfil inmunohistoquímico en mujeres con cáncer de mama atendidas en el Hospital Bertha Calderón Roque en el período de Enero 2016- Enero 2017. (internet). Universidad nacional autónoma de Nicaragua unan- Managua; 2017 (citado 19 octubre de 2020). Disponible en: http://repositorio.umam.edu.ni/4374/1/96863.pdf
7- López García,. Características histopatológicas e inmunohistoquímicas de los carcinomas de mama diagnosticados en programas de cribado de cáncer de mama. Sevilla. 2018.https://www.juntadeandalucia.es/salud/portaldeetica/xhtml/ayuda/verificarFirmaDocumento.iface/code/cf241064284d6c5ec6a605aed5ce489a4cdc5bcd
8- Maffus-Aziz A, Labastida- Almendaro S, Espejo- Fonseca A, Rodríguez- Cuevas S. Clinical and pathological features of breast cancer in a population of Mexico. Cirugía y Cirujanos. (Internet). May- June 2017 (citado 19 octubre 2020); 85 (3): aprox. 6p. Disponible en: http://www.sciencedirect.com/science/article/pii/S000974111630069X
9- American Cancer Society. Breast Cancer Fact& Figures 2019- 2020. Atlanta: American Cancer Society, Inc. 2019.
10- Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/ HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res Treat. 2017;165(3):743-750.
11- Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 Jan 19;354(3):270-82. doi: 10.1056/NEJMra050776. PMID: 16421368.
12- Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol (Lausanne). 2021 Mar 25; 12:599586. doi: 10.3389/fendo.2021.599586. Erratum in: Front Endocrinol (Lausanne). 2021 May 11;12:689705. PMID: 33841325; PMCID: PMC8030661.
13- Harold J. Burstein, M.D. Systemic Therapy for Estrogen Receptor– Positive, HER2-Negative Breast Cancer. N Engl J Med 2020; 383:2557-70.
14- Marrazzo E, Frusone F, Milana F. Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020 Feb; 49:87-92. doi: 10.1016/j.breast.2019.11.002. Epub 2019 Nov 11. PMID: 31783314; PMCID: PMC7375663.
15- Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. doi: 10.1038/nrclinonc.2016.195. Epub 2016 Dec 20. PMID: 27995946.
16- González- Müler C. Características patológicas asociadas al carcinoma de mama Her-2 positivo. An. Fac. med (Internet). 2005 Jun (citado 19 octubre 2020); 66(2): 89-99. Disponible en: http://www.scielo.org.pe/scielo.php?script=aci_arttext&pid=S1025-55832005000200002&Ing=es
17- Esparza Ortega, M.A; Tapia Calvopiña, M.P. Determinación de marcadores tumorales por Inmunohistoquímica en muestras histopatológicas de pacientes con diagnóstico de Cáncer de Mama durante el periodo 2014-2017 en el Hospital San Francisco de Quito. Ecuador, 2019.
18- Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;28:28.
19- Palacios J., Matías-Guiu X., Rodríguez-Peralto J. L., Retos e implicaciones clínicas de la heterogeneidad intratumoral. Revista Española de Patología. 2019; 52(4):234-241. https://doi.org/10.1016/j.patol.2019.04.004
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
